SpreadIt News | Digital Newspaper

Lancet Infectious Diseases Journal study revealed Covaxin is 50% effective against Delta Variant of COVID-19

An assessment to understand the effectiveness of the two dosages of Covaxin when dealing with the Delta Variant of COVID-19 in an interim study conducted by The Lancet Infectious Diseases Journal.

The interim study by Lancet was conducted on 2714 workers of the All India Institute of Medical Sciences ( AIIMS) in Delhi from April 15th to May 15th.


The AIIMS hospital workers were found to be Symptomatic & had to undergo the RT-PCR test; Lancet tests had revealed that the two dosages of Covaxin or BBV152 had given the effectiveness of 77.8 per cent against symptomatic diseases, but there were no serious issues regarding the safety of the infected person.

It was categorically observed by the research team from Lancet that the Delta Strain Variant of COVID-19 was the dominant variant found in nearly 80 per cent of the persons taken for the study.


Hyderabad-based pharma company Bharat Biotech had developed the Covaxin collaborating with the National Institute of Virology, the Indian Council of Medical Research (NIV-ICMR), in Pune, Maharashtra.

Covaxin is defined as a whole virus vaccine; this has to be administered to the infected person in two doses, both of which are to be given to the person approximately 28 days apart from each other.


January last year was the period when Covaxin was approved for emergency usage in India for patients aged 18 years and above.

The World Health Organization (WHO) earlier this month has included Covaxin in its lists of medications to be used in emergencies against COVID-19.


This study was conducted during the peak of the second wave surging of COVID-19; the Covaxin was primarily used on health care workers who were in the field for a longer period of time.

Professor Manish Soneja stated that the study had made it possible for them to understand how the Covaxin performs in the field given the immediate surge of COVID-19 in India during the said period, also with the possibility that the new delta variant could probably evade the effects of the vaccine.


The study of 2714 employees brought forward that 1617 employees were positively infected with SARS-CoV-2, which is the main virus causing COVID-19, while 1097 tested out negative.

The tests resulted in 50% effectiveness of Covaxin after administering two dosages before undergoing the RT-PCR test; several factors might be affecting the result like; the study cases were basically hospital workers who were prone to a higher risk than the general public.